Development and Validation of Liquid Chromatography/Stable Isotope-Dilution Tandem Mass Spectrometry Method for Measurement of Dexamethasone, Total Cortisol and Free Cortisol in Human Plasma

Yıl 2023, Cilt: 7 Sayı: 1, 516 - 524, 31.01.2023

Gamze Tuna , Melis Kant , Merve Akış , Serkan Yener , Gül Hüray İşlekel

https://doi.org/10.30621/jbachs.1214727

Öz

Background Cortisol plays a role in the regulation of metabolic homeostasis. Dexamethasone is a powerful synthetic glucocorticoid that acts as an anti-inflammatory and immunosuppressive agent. Plasma free cortisol, which has a low concentration in the blood, is the cortisol fraction that provides biological activity. It is emphasized that measurement of dexamethasone, total and free cortisol levels can directly affect the results of dexamethasone suppression test, which is routinely used to exclude endogenous hypercortisolemia in patients with adrenal adenoma, and is important in differential diagnosis.
Purpose In this study, a precise and rapid method was developed for the measurement of dexamethasone, total and free cortisol levels in plasma samples, besides demonstrating the clinical applicability of the method with samples from adrenal adenoma patients.
Methods Method optimization studies were performed using liquid chromatography-tandem mass spectrometry with stable isotope dilution-multiple reaction monitoring.
Results The assay demonstrated a good linear dynamic range of 0.5–20 μg/L, 5–200 μg/L and 0.5–100 μg/L for dexamethasone, total and free cortisol, respectively. The values for intra- and inter-day precisions of analytes were ≤6.9% with the accuracies ranging from 91.6% to 113.0%.
Conclusion Measurement of these parameters can be used reliably to diagnose diseases causing hypercortisolemia.

Anahtar Kelimeler

Adrenal adenoma, dexamethasone, free cortisol, LC-MS/MS, method validation, total cortisol

Destekleyen Kurum

TUBİTAK (Scientific and Research Council of Turkey)

Proje Numarası

215S632

Kaynakça

• Ebbehoj A, Li D, Kaur RJ, et al. Epidemiology of adrenal tumours in Olmsted County, Minnesota, USA: a population-based cohort study. Lancet Diabetes Endocrinol. 2020;8(11):894–902.
• Reimondo G, Castellano E, Grosso M, et al. Adrenal Incidentalomas are Tied to Increased Risk of Diabetes: Findings from a Prospective Study. J Clin Endocrinol Metab. 2020;105(4):e973–81.
• Ioachimescu AG, Remer EM, Hamrahian AH. Adrenal Incidentalomas. Endocrinol Metab Clin North Am. 2015;44(2):335–54.
• Kannan S, Remer EM, Hamrahian AH. Evaluation of patients with adrena incidentalomas. Curr Opin Endocrinol Diabetes Obes. 2013;20(3):161–9. Buske-Kirschbaum A. Cortisol Responses to Stress in Allergic Children: Interaction with the Immune Response. Neuroimmunomodulation. 2009;16(5):325–32.
• Raff H, Carroll T. Cushing’s syndrome: from physiological principles to diagnosis and clinical care. J Physiol. 2015;593(3):493–506.
• Ray JA, Kushnir MM, Rockwood AL, Meikle AW. Analysis of cortisol, cortisone and dexamethasone in human serum using liquid chromatography tandem mass spectrometry and assessment of cortisol: Cortisone ratios in patients with impaired kidney function. Clinica Chimica Acta. 2011;412(13–14):1221–8.
• Huang W, Kalhorn TF, Baillie M, Shen DD, Thummel KE. Determination of Free and Total Cortisol in Plasma and Urine by Liquid Chromatography-Tandem Mass Spectrometry. Ther Drug Monit. 2007;29(2):215–24.
• Reimondo G, Bovio S, Allasino B, et al. The combined low-dose dexamethasone suppression corticotropin-releasing hormone test as a tool to rule out Cushing’s syndrome. Eur J Endocrinol. 2008;159(5):569–76.
• Ness-Abramof R, Nabriski D, Apovian CM, et al. Overnight Dexamethasone Suppression Test: A Reliable Screen for Cushing’s Syndrome in the Obese. Obes Res. 2002;10(12):1217–21.
• Ma Y, Chen H, Chen F, et al. Mass spectrometrybased cortisol profiling during adrenal venous sampling reveals misdiagnosis for subtyping primary aldosteronism. Clin Endocrinol (Oxf). 2022;96(5):680–9.
• Chafkin JE, O’Brien JM, Medrano FN, Lee HY, Yeager DS, Josephs RA. Chemiluminescent immunoassay overestimates hormone concentrations and obscures testosterone sex differences relative to LC-MS/MS in a field study of diverse adolescents. Compr Psychoneuroendocrinol. 2022;10:100132.
• Huang W, Kalhorn TF, Baillie M, Shen DD, Thummel KE. Determination of free and total cortisol in plasma and urine by liquid chromatography-tandem mass spectrometry. Ther Drug Monit. 2007;29(2):215–24.
• Yener S, Tuna G, Kant M, et al. Assessment of Plasma-Free Cortisol Concentrations by LCMS/MS in Patients with Autonomous Cortisol Secretion. Hormone and Metabolic Research. 2021;53(11):752–8.
• Ray JA, Kushnir MM, Rockwood AL, Meikle AW. Analysis of cortisol, cortisone and dexamethasone in human serum using liquid chromatography tandem mass spectrometry and assessment of cortisol: Cortisone ratios in patients with impaired kidney function. Clinica Chimica Acta. 2011;412(13–14):1221–8.
• C62-A Liquid Chromatography-Mass Spectrometry Methods; Approved Guideline A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process [Internet]. 2014. Available from: www.clsi.org.
• C50-A Mass Spectrometry in the Clinical Laboratory: General Principles and Guidance; Approved Guideline A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process [Internet]. 2007. Available from: www.clsi.org.
• Shah VP, Midha KK, Findlay JWA, et al. Bioanalytical Method Validation—A Revisit with a Decade of Progress. Pharm Res. 2000;17(12):1551–7.
• McWhinney BC, Briscoe SE, Ungerer JPJ, Pretorius CJ. Measurement of cortisol, cortisone, prednisolone, dexamethasone and 11- deoxycortisol with ultra high performance liquid chromatography–tandem mass spectrometry: Application for plasma, plasma ultrafiltrate, urine and saliva in a routine laboratory. Journal of Chromatography B. 2010;878(28):2863–9.
• Casals G, Hanzu FA. Cortisol Measurements in Cushing’s Syndrome: Immunoassay or Mass Spectrometry? Ann Lab Med. 2020;40(4):285– 96.
• Honour JW. Standardization of steroid tests and implications for the endocrine community. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine. 2017;54(6):628–30.
• Miller R, Plessow F, Rauh M, Gr.schl M, Kirschbaum C. Comparison of salivary cortisol as measured by different immunoassays and tandem mass spectrometry. Psychoneuroendocrinology. 2013;38(1):50–7.
• El-Farhan N, Pickett A, Ducroq D, et al. Methodspecific serum cortisol responses to the adrenocorticotrophin test: comparison of gas chromatography-mass spectrometry and five automated immunoassays. Clin Endocrinol (Oxf). 2013;78(5):673–80.
• Taylor AE, Keevil B, Huhtaniemi IT. Mass spectrometry and immunoassay: how to measure steroid hormones today and tomorrow. Eur J Endocrinol. 2015;173(2):D1–12.